Solid Biosciences (SLDB) EBT (2017 - 2026)

Solid Biosciences has disclosed EBT across 10 years of filings, most recently posting -$55.2 million for Q1 2026.

• EBT for Q1 2026 came in at -$55.2 million, down 46.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$186.5 million (down 39.08% YoY), and the FY2025 annual result was -$169.1 million, down 40.22% from the prior year.
• EBT came in at -$55.2 million for Q1 2026 at Solid Biosciences, down from -$47.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$20.4 million in Q3 2022 to a low of -$55.2 million in Q1 2026.
• The 5-year median for EBT is -$30.4 million (2023), against an average of -$32.1 million.
• Across the five-year window, EBT soared 37.62% in 2023 and slumped 84.64% in 2024, its largest moves.
• Solid Biosciences' EBT stood at -$33.0 million in 2022, then jumped by 37.62% to -$20.6 million in 2023, then plunged by 84.64% to -$38.0 million in 2024, then declined by 24.47% to -$47.4 million in 2025, then dropped by 16.66% to -$55.2 million in 2026.
• The last three EBT figures came in at -$55.2 million (Q1 2026), -$47.4 million (Q4 2025), and -$45.1 million (Q3 2025), per Business Quant data.